Seeking Alpha

The FDA supports exploring with Orexigen Therapeutics (OREX +4.9%) how the firm can speed up its...

The FDA supports exploring with Orexigen Therapeutics (OREX +4.9%) how the firm can speed up its application for weight loss pill Contrave. The FDA rejected the drug in January 2011, due to possible heart problems, and asked Orexigen to conduct another study. The company has so far enrolled 7,000 patients and intends to recruit another 9,000 by the year-end. (PR)
Comments (1)
  • user418
    , contributor
    Comments (217) | Send Message
     
    fda is not fair !!! to put it politely.
    22 Oct 2012, 10:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector